A lot of things cause hives, which are medically known as urticaria: allergies, medications, heat, cold, sunlight, even stress. But here’s a cause you probably didn’t have on your bingo card: water.

NPC is an ultra-rare, relentlessly progressive, genetic disorder that leads to premature mortality. MIPLYFFA, used in conjunction with miglustat, is the only treatment shown to halt disease ...

A multicentre retrospective study has found that chronic spontaneous urticaria (CSU) occurring in patients with systemic ...

Pathophysiologic biomarkers for chronic spontaneous urticaria (CSU) are emerging, which can help better target therapies for ...

Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...

The most common side effects of NUCALA include: headache, injection site reactions (pain, redness, swelling, itching, or a ...

In patients with chronic spontaneous urticaria (CSU) unresponsive to H1-antihistamines, re-treatment with ligelizumab was effective and mostly well tolerated, with both 72-mg and 120-mg doses yielding ...

Patients with chronic spontaneous urticaria (CSU) often experience impaired QOL, especially when antihistamines, the standard treatment, have failed. Some patients with CSU experience intense itching, ...

Patients with chronic spontaneous urticaria experienced relief in itch and hives by day 3 with povorcitinib, according to data presented at the American College of Allergy, Asthma & Immunology Annual ...

In September 2025, the US Food and Drug Administration (FDA) approved Rhapsido ® (remibrutinib), an oral small molecule kinase inhibitor, for the treatment of chronic spontaneous urticaria (CSU) in ...

In other recent news, Celldex Therapeutics announced positive data for its treatment barzolvolimab, which showed significant improvements in urticaria control in patients with chronic spontaneous ...